April 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Roll Call			Present: Dr. Swee, Dr. Moynihan, Dr. Woodward, Ms. Rodriguez, Mr. Schafer, Dr. Marcus, Dr. Gochfeld, Dr. Moore, Dr. Condoluci, Ms. Olson, Dr. Zanna, Mr. Vaccaro, Dr. Lichtbroun Absent: Dr. Cavalieri, Dr. Barberio, Dr. Gooen
Review of Minutes	Pages 3-6; Tab 1	Approved	Minutes from the January 2007 meeting were approved.
Secretary's Report	Pages 7-13; Tab 2		All previous recommendations have been accepted and are in the process of being implemented. The Board's recommendation to include HMO denial reporting will be included in the new HMO contract effective July 2007 and will be available for the January 2008 meeting. The Osteoporosis and Insomnia newsletters are available at www.state.nj.us/humanservices/dmahs/durb/html . The serotonin syndrome publication is being worked on once the data analysis has been completed it will be presented to the Board.
Business			
A. Medicaid Programs and Populations	Pages 13-17; Tab 3		Kaye Morrow presented information on the Medicaid programs and populations for the Board.
B. Adverse Drug Reactions (ADR) data/Serotonin syndrome publication		Tabled	Due to difficulties in data collection and data analysis, discussion on this topic was tabled. The State is currently working on analyzing the data generated from claims.
C. Suboxone/opioid protocol	Pages 19; Tab 4	Approved	The Board recommended that the State adopt the protocol as presented.
D. Modafinil	Pages 21-26; Tab 5	Approved with revision	The Board recommended that the State adopt the protocol as presented in addition to the use of antipsychotic medications as criteria for approval of modafinil.
E. OTC pilot program	Page 27; Tab 6	Approved	The Board recommended that the State cover OTC ophthalmic solutions that are indicated for treatment of allergic conjunctivitis as an alternative to the legend products in appropriate patients. The OTC products being prescribed must be presented as a written prescription.

***refers to Pages and Tabs in April 2007 DURB Agenda**

April 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
H. Informational Highlights			
1. Safety Alert-Aranesp/Public Health Advisory-ESAs	Pages 29-32; Tab 7		The Board would like the State to provide information from the renal dialysis units and their criteria for treatment with ESAs in particular the hemoglobin level to initiate or terminate therapy with ESAs.
2. Label change for sleep disorder products	Pages 33-34; Tab 8		The FDA requested that manufacturers of sedative-hypnotics revise their product labeling to include warnings concerning anaphylaxis, angioedema and complex sleep-related behaviors.
3. State Police news release	Pages 35-37; Tab 9		
4. Unisys reports	Pages 39-42; Tab 10		The Board would like the State to report the percentage of prescriptions approved and denied to the total number of prescriptions processed.
5. Top 200 drugs	Tab 11		Board members received report on Top 200 drugs but no discussion.
H. Action Items			
1. ESAs 2. HMO enrollment 3. Disease Management 4. HMO denial reporting 5. modafinil and antipsychotics data 6. Unisys clinical denials			1. Present renal dialysis units' protocols for use of ESAs. 2. Present the number of clients enrolled in individual New Jersey HMOs. 3. Provide Board with CNS and APS disease management website and description 4. Denial reporting from HMOs will be available for the Board January 2008. 5. Present data on the use of modafinil in patients concomitantly utilizing antipsychotics. 6. The board would like the data presented in terms of prescriptions approved or denied compared to the total number of prescriptions processed.

***refers to Pages and Tabs in April 2007 DURB Agenda**